Categories
Life Sciences Consumer Goods Materials and Chemicals Construction & Manufacturing Food and Beverages Energy and Power Semiconductor and Electronics Automotive and Transportation ICT & Media Aerospace & Defense BFSI

Int'l : +1-503-894-6022 | Toll Free : +1-800-792-5285 | help@alliedmarketresearch.com

Reperfusion Therapy Market by Application Type (Coronary Angioplasty, Coronary Artery Bypass Surgery), by Drug (Fibrinolytics, Thrombolytics) and by End User (Hospitals, Ambulatory surgery centers, Others): Global Opportunity Analysis and Industry Forecast, 2023-2032

A11234

Pages: NA

Charts: NA

Tables: NA

Reperfusion therapy is a medical treatment that is used to restore blood flow, either around blocked arteries, basically after a heart attack or myocardial infarction (MI). This therapy includes drugs and surgery. The drugs which can be used include thrombolytic and fibrinolysis used in a process and is called thrombolysis. The surgeries performed may be minimally-invasive endovascular procedures such as coronary angioplasty, percutaneous coronary intervention (PCI). The angioplasty utilizes the insertion of a balloon to open up the artery, with the possible additional use of one or more stents. The various other surgeries performed are the higher invasive bypass surgeries that graft arteries around blockages.

COVID-19 scenario analysis:

The rise in the number of individuals experiencing coronavirus disease-2 has led a global concern for protection, due to which lockout situation was declared. Due to this lockout situation, there has been a halt in the manufacturing of various pharmaceutical products, which is causing economic recession. The Covid-19 pandemic has negatively impacted on the healthcare system, and causing about 50% to 70% drop in revenue since March. The smaller organizations such as, small hospitals, clinics and nursing homes, are announced to be kept shut during the period, and hence affected the economic growth of the majority of the sectors. This is has reduced the number of the surgical procedures. Furthermore, rise in number of visa cancellations has reduced revenue due to medical tourism, hence is affecting the economy negatively in the current scenario.

Top impacting factors: Market Scenario Analysis, Trends, Drivers and Impact Analysis

The key factors affecting the industrial growth include the rise in number of cardiovascular diseases and increase in individuals adapting unhealthy lifestyle, which would help the market grow significantly during the forecast period. Furthermore, rise in geriatric population would help the market boost in the coming year. However, the lack of skilled professionals, may hinder the industrial growth in the commenced period.

New product advancements to flourish the market

In July 2016, Penumbra announced the launch of the Ace68 Reperfusion thrombectomy catheter in the U.S. This product is designed for extracting thrombus in acute ischemic stroke patients mainly. The Ace68 catheter was engineered on an entirely novel platform from hub to tip, which features coil winding geometry along 16 transitions to create a more optimal tracking profile.

In July 2019, Penumbra announced commercial availability of the Penumbra System’s most advanced technology in the U.S. The Penumbra Jet 7 Reperfusion Catheter with Xtra Flex technology, at the Society of NeuroInterventional Surgery (SNIS) 16th Annual Meeting. Penumbra Jet 7 with Xtra Flex technology is used with the Penumbra Engine in the fully integrated Penumbra System, an aspiration-based mechanical thrombectomy system that allows physicians to extract thrombus in acute ischemic stroke patients.

Surge in incidences of the diseases which need the therapy to boost the market

According to the estimates given by the World Health Organization, the major cause of death is cardiovascular diseases. The number deaths are about 17.9 million, caused due to cardiovascular diseases. Four out of Five of the Cardiovascular Diseases, are the deaths due to heart attacks and strokes, and one third of these deaths occur earlier in people, who are under 70 years of age.

According to the estimates given by the Center of Disease Control and Prevention, the heart diseases are among the major causes of deaths in the U.S., one person dies every 37 seconds. This alarming rate has drastically gained the attention of the majority of the population.

Key benefits of the report:

  • This study presents the analytical depiction of the global reperfusion therapy industry along with the current trends and future estimations to determine the imminent investment pockets.
  • The report presents information related to key drivers, restraints, and opportunities along with detailed analysis of the global reperfusion therapy market share.
  • The current market is quantitatively analyzed to highlight the global reperfusion therapy market growth scenario.
  • Porter’s five forces analysis illustrates the potency of buyers & suppliers in the market.
  • The report provides a detailed global reperfusion therapy market analysis based on competitive intensity and how the competition will take shape in coming years.

Questions answered in the reperfusion therapy market research report:

  • What are the leading market players active in the reperfusion therapy market?
  • What current trends will influence the market in the next few years?
  • What are the driving factors, restraints, and opportunities in the market?
  • What are the projections for the future that would help in tasking further strategic steps?

Key Market Segments

  • By Application Type
    • Coronary Angioplasty
    • Coronary Artery Bypass Surgery
  • By Drug
    • Fibrinolytics
    • Thrombolytics
  • By End User
    • Hospitals
    • Ambulatory surgery centers
    • Others
  • By Region
    • North America
      • U.S.
      • Canada
      • Mexico
    • Europe
      • France
      • Germany
      • Italy
      • Spain
      • UK
      • Rest of Europe
    • Asia-Pacific
      • China
      • Japan
      • India
      • South Korea
      • Australia
      • Rest of Asia-Pacific
    • LAMEA
      • Brazil
      • South Africa
      • Saudi Arabia
      • UAE
      • Rest of LAMEA


Key Market Players

  • Balmes Transplantation SAS
  • Pharming Group NV
  • Mallinckrodt Pharmaceuticals
  • Faraday Pharmaceuticals
  • MIFCOR, Inc.
  • Amyndas Pharmaceuticals
  • Angion Biomedica Corp.
  • CFM Pharma Holding B.V.
  • SBI Holdings Inc.
  • Radikal Therapeutics Inc.
  • Corline Biomedical AB
  • Revive Therapeutics Ltd.
  • CHAPTER 1: INTRODUCTION

    • 1.1. Report Description

    • 1.2. Key Market Segments

    • 1.3. Key Benefits

    • 1.4. Research Methodology

      • 1.4.1. Primary Research

      • 1.4.2. Secondary Research

      • 1.4.3. Analyst Tools and Models

  • CHAPTER 2: EXECUTIVE SUMMARY

    • 2.1. CXO Perspective

  • CHAPTER 3: MARKET LANDSCAPE

    • 3.1. Market Definition and Scope

    • 3.2. Key Findings

      • 3.2.1. Top Investment Pockets

      • 3.2.2. Top Winning Strategies

    • 3.3. Porter's Five Forces Analysis

      • 3.3.1. Bargaining Power of Suppliers

      • 3.3.2. Threat of New Entrants

      • 3.3.3. Threat of Substitutes

      • 3.3.4. Competitive Rivalry

      • 3.3.5. Bargaining Power among Buyers

    • 3.5. Market Dynamics

      • 3.5.1. Drivers

      • 3.5.2. Restraints

      • 3.5.3. Opportunities

  • CHAPTER 4: REPERFUSION THERAPY MARKET, BY APPLICATION TYPE

    • 4.1. Market Overview

      • 4.1.1 Market Size and Forecast, By Application Type

    • 4.2. Coronary Angioplasty

      • 4.2.1. Key Market Trends, Growth Factors and Opportunities

      • 4.2.2. Market Size and Forecast, By Region

      • 4.2.3. Market Share Analysis, By Country

    • 4.3. Coronary Artery Pass Surgery

      • 4.3.1. Key Market Trends, Growth Factors and Opportunities

      • 4.3.2. Market Size and Forecast, By Region

      • 4.3.3. Market Share Analysis, By Country

  • CHAPTER 5: REPERFUSION THERAPY MARKET, BY DRUG

    • 5.1. Market Overview

      • 5.1.1 Market Size and Forecast, By Drug

    • 5.2. Fibrinolytics

      • 5.2.1. Key Market Trends, Growth Factors and Opportunities

      • 5.2.2. Market Size and Forecast, By Region

      • 5.2.3. Market Share Analysis, By Country

    • 5.3. Thrombolytics

      • 5.3.1. Key Market Trends, Growth Factors and Opportunities

      • 5.3.2. Market Size and Forecast, By Region

      • 5.3.3. Market Share Analysis, By Country

  • CHAPTER 6: REPERFUSION THERAPY MARKET, BY END USER

    • 6.1. Market Overview

      • 6.1.1 Market Size and Forecast, By End User

    • 6.2. Hospitals

      • 6.2.1. Key Market Trends, Growth Factors and Opportunities

      • 6.2.2. Market Size and Forecast, By Region

      • 6.2.3. Market Share Analysis, By Country

    • 6.3. Ambulatory Surgery Centers

      • 6.3.1. Key Market Trends, Growth Factors and Opportunities

      • 6.3.2. Market Size and Forecast, By Region

      • 6.3.3. Market Share Analysis, By Country

    • 6.4. Others

      • 6.4.1. Key Market Trends, Growth Factors and Opportunities

      • 6.4.2. Market Size and Forecast, By Region

      • 6.4.3. Market Share Analysis, By Country

  • CHAPTER 7: REPERFUSION THERAPY MARKET, BY REGION

    • 7.1. Market Overview

      • 7.1.1 Market Size and Forecast, By Region

    • 7.2. North America

      • 7.2.1. Key Market Trends and Opportunities

      • 7.2.2. Market Size and Forecast, By Application Type

      • 7.2.3. Market Size and Forecast, By Drug

      • 7.2.4. Market Size and Forecast, By End User

      • 7.2.5. Market Size and Forecast, By Country

      • 7.2.6. U.S. Reperfusion Therapy Market

        • 7.2.6.1. Market Size and Forecast, By Application Type
        • 7.2.6.2. Market Size and Forecast, By Drug
        • 7.2.6.3. Market Size and Forecast, By End User
      • 7.2.7. Canada Reperfusion Therapy Market

        • 7.2.7.1. Market Size and Forecast, By Application Type
        • 7.2.7.2. Market Size and Forecast, By Drug
        • 7.2.7.3. Market Size and Forecast, By End User
      • 7.2.8. Mexico Reperfusion Therapy Market

        • 7.2.8.1. Market Size and Forecast, By Application Type
        • 7.2.8.2. Market Size and Forecast, By Drug
        • 7.2.8.3. Market Size and Forecast, By End User
    • 7.3. Europe

      • 7.3.1. Key Market Trends and Opportunities

      • 7.3.2. Market Size and Forecast, By Application Type

      • 7.3.3. Market Size and Forecast, By Drug

      • 7.3.4. Market Size and Forecast, By End User

      • 7.3.5. Market Size and Forecast, By Country

      • 7.3.6. France Reperfusion Therapy Market

        • 7.3.6.1. Market Size and Forecast, By Application Type
        • 7.3.6.2. Market Size and Forecast, By Drug
        • 7.3.6.3. Market Size and Forecast, By End User
      • 7.3.7. Germany Reperfusion Therapy Market

        • 7.3.7.1. Market Size and Forecast, By Application Type
        • 7.3.7.2. Market Size and Forecast, By Drug
        • 7.3.7.3. Market Size and Forecast, By End User
      • 7.3.8. Italy Reperfusion Therapy Market

        • 7.3.8.1. Market Size and Forecast, By Application Type
        • 7.3.8.2. Market Size and Forecast, By Drug
        • 7.3.8.3. Market Size and Forecast, By End User
      • 7.3.9. Spain Reperfusion Therapy Market

        • 7.3.9.1. Market Size and Forecast, By Application Type
        • 7.3.9.2. Market Size and Forecast, By Drug
        • 7.3.9.3. Market Size and Forecast, By End User
      • 7.3.10. UK Reperfusion Therapy Market

        • 7.3.10.1. Market Size and Forecast, By Application Type
        • 7.3.10.2. Market Size and Forecast, By Drug
        • 7.3.10.3. Market Size and Forecast, By End User
      • 7.3.11. Russia Reperfusion Therapy Market

        • 7.3.11.1. Market Size and Forecast, By Application Type
        • 7.3.11.2. Market Size and Forecast, By Drug
        • 7.3.11.3. Market Size and Forecast, By End User
      • 7.3.12. Rest Of Europe Reperfusion Therapy Market

        • 7.3.12.1. Market Size and Forecast, By Application Type
        • 7.3.12.2. Market Size and Forecast, By Drug
        • 7.3.12.3. Market Size and Forecast, By End User
    • 7.4. Asia-Pacific

      • 7.4.1. Key Market Trends and Opportunities

      • 7.4.2. Market Size and Forecast, By Application Type

      • 7.4.3. Market Size and Forecast, By Drug

      • 7.4.4. Market Size and Forecast, By End User

      • 7.4.5. Market Size and Forecast, By Country

      • 7.4.6. China Reperfusion Therapy Market

        • 7.4.6.1. Market Size and Forecast, By Application Type
        • 7.4.6.2. Market Size and Forecast, By Drug
        • 7.4.6.3. Market Size and Forecast, By End User
      • 7.4.7. Japan Reperfusion Therapy Market

        • 7.4.7.1. Market Size and Forecast, By Application Type
        • 7.4.7.2. Market Size and Forecast, By Drug
        • 7.4.7.3. Market Size and Forecast, By End User
      • 7.4.8. India Reperfusion Therapy Market

        • 7.4.8.1. Market Size and Forecast, By Application Type
        • 7.4.8.2. Market Size and Forecast, By Drug
        • 7.4.8.3. Market Size and Forecast, By End User
      • 7.4.9. South Korea Reperfusion Therapy Market

        • 7.4.9.1. Market Size and Forecast, By Application Type
        • 7.4.9.2. Market Size and Forecast, By Drug
        • 7.4.9.3. Market Size and Forecast, By End User
      • 7.4.10. Australia Reperfusion Therapy Market

        • 7.4.10.1. Market Size and Forecast, By Application Type
        • 7.4.10.2. Market Size and Forecast, By Drug
        • 7.4.10.3. Market Size and Forecast, By End User
      • 7.4.11. Thailand Reperfusion Therapy Market

        • 7.4.11.1. Market Size and Forecast, By Application Type
        • 7.4.11.2. Market Size and Forecast, By Drug
        • 7.4.11.3. Market Size and Forecast, By End User
      • 7.4.12. Malaysia Reperfusion Therapy Market

        • 7.4.12.1. Market Size and Forecast, By Application Type
        • 7.4.12.2. Market Size and Forecast, By Drug
        • 7.4.12.3. Market Size and Forecast, By End User
      • 7.4.13. Indonesia Reperfusion Therapy Market

        • 7.4.13.1. Market Size and Forecast, By Application Type
        • 7.4.13.2. Market Size and Forecast, By Drug
        • 7.4.13.3. Market Size and Forecast, By End User
      • 7.4.14. Rest of Asia Pacific Reperfusion Therapy Market

        • 7.4.14.1. Market Size and Forecast, By Application Type
        • 7.4.14.2. Market Size and Forecast, By Drug
        • 7.4.14.3. Market Size and Forecast, By End User
    • 7.5. LAMEA

      • 7.5.1. Key Market Trends and Opportunities

      • 7.5.2. Market Size and Forecast, By Application Type

      • 7.5.3. Market Size and Forecast, By Drug

      • 7.5.4. Market Size and Forecast, By End User

      • 7.5.5. Market Size and Forecast, By Country

      • 7.5.6. Brazil Reperfusion Therapy Market

        • 7.5.6.1. Market Size and Forecast, By Application Type
        • 7.5.6.2. Market Size and Forecast, By Drug
        • 7.5.6.3. Market Size and Forecast, By End User
      • 7.5.7. South Africa Reperfusion Therapy Market

        • 7.5.7.1. Market Size and Forecast, By Application Type
        • 7.5.7.2. Market Size and Forecast, By Drug
        • 7.5.7.3. Market Size and Forecast, By End User
      • 7.5.8. Saudi Arabia Reperfusion Therapy Market

        • 7.5.8.1. Market Size and Forecast, By Application Type
        • 7.5.8.2. Market Size and Forecast, By Drug
        • 7.5.8.3. Market Size and Forecast, By End User
      • 7.5.9. UAE Reperfusion Therapy Market

        • 7.5.9.1. Market Size and Forecast, By Application Type
        • 7.5.9.2. Market Size and Forecast, By Drug
        • 7.5.9.3. Market Size and Forecast, By End User
      • 7.5.10. Argentina Reperfusion Therapy Market

        • 7.5.10.1. Market Size and Forecast, By Application Type
        • 7.5.10.2. Market Size and Forecast, By Drug
        • 7.5.10.3. Market Size and Forecast, By End User
      • 7.5.11. Rest of LAMEA Reperfusion Therapy Market

        • 7.5.11.1. Market Size and Forecast, By Application Type
        • 7.5.11.2. Market Size and Forecast, By Drug
        • 7.5.11.3. Market Size and Forecast, By End User
  • CHAPTER 8: COMPETITIVE LANDSCAPE

    • 8.1. Introduction

    • 8.2. Top Winning Strategies

    • 8.3. Product Mapping Of Top 10 Player

    • 8.4. Competitive Dashboard

    • 8.5. Competitive Heatmap

    • 8.6. Top Player Positioning, 2024

  • CHAPTER 9: COMPANY PROFILES

    • 9.1. Corline Biomedical AB

      • 9.1.1. Company Overview

      • 9.1.2. Key Executives

      • 9.1.3. Company Snapshot

      • 9.1.4. Operating Business Segments

      • 9.1.5. Product Portfolio

      • 9.1.6. Business Performance

      • 9.1.7. Key Strategic Moves and Developments

    • 9.2. SBI Holdings Inc.

      • 9.2.1. Company Overview

      • 9.2.2. Key Executives

      • 9.2.3. Company Snapshot

      • 9.2.4. Operating Business Segments

      • 9.2.5. Product Portfolio

      • 9.2.6. Business Performance

      • 9.2.7. Key Strategic Moves and Developments

    • 9.3. Pharming Group NV

      • 9.3.1. Company Overview

      • 9.3.2. Key Executives

      • 9.3.3. Company Snapshot

      • 9.3.4. Operating Business Segments

      • 9.3.5. Product Portfolio

      • 9.3.6. Business Performance

      • 9.3.7. Key Strategic Moves and Developments

    • 9.4. Mallinckrodt Pharmaceuticals

      • 9.4.1. Company Overview

      • 9.4.2. Key Executives

      • 9.4.3. Company Snapshot

      • 9.4.4. Operating Business Segments

      • 9.4.5. Product Portfolio

      • 9.4.6. Business Performance

      • 9.4.7. Key Strategic Moves and Developments

    • 9.5. MIFCOR, Inc.

      • 9.5.1. Company Overview

      • 9.5.2. Key Executives

      • 9.5.3. Company Snapshot

      • 9.5.4. Operating Business Segments

      • 9.5.5. Product Portfolio

      • 9.5.6. Business Performance

      • 9.5.7. Key Strategic Moves and Developments

    • 9.6. CFM Pharma Holding B.V.

      • 9.6.1. Company Overview

      • 9.6.2. Key Executives

      • 9.6.3. Company Snapshot

      • 9.6.4. Operating Business Segments

      • 9.6.5. Product Portfolio

      • 9.6.6. Business Performance

      • 9.6.7. Key Strategic Moves and Developments

    • 9.7. Balmes Transplantation SAS

      • 9.7.1. Company Overview

      • 9.7.2. Key Executives

      • 9.7.3. Company Snapshot

      • 9.7.4. Operating Business Segments

      • 9.7.5. Product Portfolio

      • 9.7.6. Business Performance

      • 9.7.7. Key Strategic Moves and Developments

    • 9.8. Revive Therapeutics Ltd.

      • 9.8.1. Company Overview

      • 9.8.2. Key Executives

      • 9.8.3. Company Snapshot

      • 9.8.4. Operating Business Segments

      • 9.8.5. Product Portfolio

      • 9.8.6. Business Performance

      • 9.8.7. Key Strategic Moves and Developments

    • 9.9. Faraday Pharmaceuticals

      • 9.9.1. Company Overview

      • 9.9.2. Key Executives

      • 9.9.3. Company Snapshot

      • 9.9.4. Operating Business Segments

      • 9.9.5. Product Portfolio

      • 9.9.6. Business Performance

      • 9.9.7. Key Strategic Moves and Developments

    • 9.10. Radikal Therapeutics Inc.

      • 9.10.1. Company Overview

      • 9.10.2. Key Executives

      • 9.10.3. Company Snapshot

      • 9.10.4. Operating Business Segments

      • 9.10.5. Product Portfolio

      • 9.10.6. Business Performance

      • 9.10.7. Key Strategic Moves and Developments

    • 9.11. Amyndas Pharmaceuticals

      • 9.11.1. Company Overview

      • 9.11.2. Key Executives

      • 9.11.3. Company Snapshot

      • 9.11.4. Operating Business Segments

      • 9.11.5. Product Portfolio

      • 9.11.6. Business Performance

      • 9.11.7. Key Strategic Moves and Developments

    • 9.12. Angion Biomedica Corp.

      • 9.12.1. Company Overview

      • 9.12.2. Key Executives

      • 9.12.3. Company Snapshot

      • 9.12.4. Operating Business Segments

      • 9.12.5. Product Portfolio

      • 9.12.6. Business Performance

      • 9.12.7. Key Strategic Moves and Developments

  • LIST OF TABLES

  • TABLE 1. GLOBAL REPERFUSION THERAPY MARKET, BY APPLICATION TYPE, 2025-2033 ($MILLION)
  • TABLE 2. GLOBAL REPERFUSION THERAPY MARKET FOR CORONARY ANGIOPLASTY, BY REGION, 2025-2033 ($MILLION)
  • TABLE 3. GLOBAL REPERFUSION THERAPY MARKET FOR CORONARY ARTERY PASS SURGERY, BY REGION, 2025-2033 ($MILLION)
  • TABLE 4. GLOBAL REPERFUSION THERAPY MARKET, BY DRUG, 2025-2033 ($MILLION)
  • TABLE 5. GLOBAL REPERFUSION THERAPY MARKET FOR FIBRINOLYTICS, BY REGION, 2025-2033 ($MILLION)
  • TABLE 6. GLOBAL REPERFUSION THERAPY MARKET FOR THROMBOLYTICS, BY REGION, 2025-2033 ($MILLION)
  • TABLE 7. GLOBAL REPERFUSION THERAPY MARKET, BY END USER, 2025-2033 ($MILLION)
  • TABLE 8. GLOBAL REPERFUSION THERAPY MARKET FOR HOSPITALS, BY REGION, 2025-2033 ($MILLION)
  • TABLE 9. GLOBAL REPERFUSION THERAPY MARKET FOR AMBULATORY SURGERY CENTERS, BY REGION, 2025-2033 ($MILLION)
  • TABLE 10. GLOBAL REPERFUSION THERAPY MARKET FOR OTHERS, BY REGION, 2025-2033 ($MILLION)
  • TABLE 11. GLOBAL REPERFUSION THERAPY MARKET, BY REGION, 2025-2033 ($MILLION)
  • TABLE 12. NORTH AMERICA REPERFUSION THERAPY, BY REGION, 2025-2033 ($MILLION)
  • TABLE 13. NORTH AMERICA REPERFUSION THERAPY, BY APPLICATION TYPE, 2025-2033 ($MILLION)
  • TABLE 14. NORTH AMERICA REPERFUSION THERAPY, BY DRUG, 2025-2033 ($MILLION)
  • TABLE 15. NORTH AMERICA REPERFUSION THERAPY, BY END USER, 2025-2033 ($MILLION)
  • TABLE 16. U.S. REPERFUSION THERAPY, BY APPLICATION TYPE, 2025-2033 ($MILLION)
  • TABLE 17. U.S. REPERFUSION THERAPY, BY DRUG, 2025-2033 ($MILLION)
  • TABLE 18. U.S. REPERFUSION THERAPY, BY END USER, 2025-2033 ($MILLION)
  • TABLE 19. CANADA REPERFUSION THERAPY, BY APPLICATION TYPE, 2025-2033 ($MILLION)
  • TABLE 20. CANADA REPERFUSION THERAPY, BY DRUG, 2025-2033 ($MILLION)
  • TABLE 21. CANADA REPERFUSION THERAPY, BY END USER, 2025-2033 ($MILLION)
  • TABLE 22. MEXICO REPERFUSION THERAPY, BY APPLICATION TYPE, 2025-2033 ($MILLION)
  • TABLE 23. MEXICO REPERFUSION THERAPY, BY DRUG, 2025-2033 ($MILLION)
  • TABLE 24. MEXICO REPERFUSION THERAPY, BY END USER, 2025-2033 ($MILLION)
  • TABLE 25. EUROPE REPERFUSION THERAPY, BY REGION, 2025-2033 ($MILLION)
  • TABLE 26. EUROPE REPERFUSION THERAPY, BY APPLICATION TYPE, 2025-2033 ($MILLION)
  • TABLE 27. EUROPE REPERFUSION THERAPY, BY DRUG, 2025-2033 ($MILLION)
  • TABLE 28. EUROPE REPERFUSION THERAPY, BY END USER, 2025-2033 ($MILLION)
  • TABLE 29. FRANCE REPERFUSION THERAPY, BY APPLICATION TYPE, 2025-2033 ($MILLION)
  • TABLE 30. FRANCE REPERFUSION THERAPY, BY DRUG, 2025-2033 ($MILLION)
  • TABLE 31. FRANCE REPERFUSION THERAPY, BY END USER, 2025-2033 ($MILLION)
  • TABLE 32. GERMANY REPERFUSION THERAPY, BY APPLICATION TYPE, 2025-2033 ($MILLION)
  • TABLE 33. GERMANY REPERFUSION THERAPY, BY DRUG, 2025-2033 ($MILLION)
  • TABLE 34. GERMANY REPERFUSION THERAPY, BY END USER, 2025-2033 ($MILLION)
  • TABLE 35. ITALY REPERFUSION THERAPY, BY APPLICATION TYPE, 2025-2033 ($MILLION)
  • TABLE 36. ITALY REPERFUSION THERAPY, BY DRUG, 2025-2033 ($MILLION)
  • TABLE 37. ITALY REPERFUSION THERAPY, BY END USER, 2025-2033 ($MILLION)
  • TABLE 38. SPAIN REPERFUSION THERAPY, BY APPLICATION TYPE, 2025-2033 ($MILLION)
  • TABLE 39. SPAIN REPERFUSION THERAPY, BY DRUG, 2025-2033 ($MILLION)
  • TABLE 40. SPAIN REPERFUSION THERAPY, BY END USER, 2025-2033 ($MILLION)
  • TABLE 41. UK REPERFUSION THERAPY, BY APPLICATION TYPE, 2025-2033 ($MILLION)
  • TABLE 42. UK REPERFUSION THERAPY, BY DRUG, 2025-2033 ($MILLION)
  • TABLE 43. UK REPERFUSION THERAPY, BY END USER, 2025-2033 ($MILLION)
  • TABLE 44. RUSSIA REPERFUSION THERAPY, BY APPLICATION TYPE, 2025-2033 ($MILLION)
  • TABLE 45. RUSSIA REPERFUSION THERAPY, BY DRUG, 2025-2033 ($MILLION)
  • TABLE 46. RUSSIA REPERFUSION THERAPY, BY END USER, 2025-2033 ($MILLION)
  • TABLE 47. REST OF EUROPE REPERFUSION THERAPY, BY APPLICATION TYPE, 2025-2033 ($MILLION)
  • TABLE 48. REST OF EUROPE REPERFUSION THERAPY, BY DRUG, 2025-2033 ($MILLION)
  • TABLE 49. REST OF EUROPE REPERFUSION THERAPY, BY END USER, 2025-2033 ($MILLION)
  • TABLE 50. ASIA-PACIFIC REPERFUSION THERAPY, BY REGION, 2025-2033 ($MILLION)
  • TABLE 51. ASIA-PACIFIC REPERFUSION THERAPY, BY APPLICATION TYPE, 2025-2033 ($MILLION)
  • TABLE 52. ASIA-PACIFIC REPERFUSION THERAPY, BY DRUG, 2025-2033 ($MILLION)
  • TABLE 53. ASIA-PACIFIC REPERFUSION THERAPY, BY END USER, 2025-2033 ($MILLION)
  • TABLE 54. CHINA REPERFUSION THERAPY, BY APPLICATION TYPE, 2025-2033 ($MILLION)
  • TABLE 55. CHINA REPERFUSION THERAPY, BY DRUG, 2025-2033 ($MILLION)
  • TABLE 56. CHINA REPERFUSION THERAPY, BY END USER, 2025-2033 ($MILLION)
  • TABLE 57. JAPAN REPERFUSION THERAPY, BY APPLICATION TYPE, 2025-2033 ($MILLION)
  • TABLE 58. JAPAN REPERFUSION THERAPY, BY DRUG, 2025-2033 ($MILLION)
  • TABLE 59. JAPAN REPERFUSION THERAPY, BY END USER, 2025-2033 ($MILLION)
  • TABLE 60. INDIA REPERFUSION THERAPY, BY APPLICATION TYPE, 2025-2033 ($MILLION)
  • TABLE 61. INDIA REPERFUSION THERAPY, BY DRUG, 2025-2033 ($MILLION)
  • TABLE 62. INDIA REPERFUSION THERAPY, BY END USER, 2025-2033 ($MILLION)
  • TABLE 63. SOUTH KOREA REPERFUSION THERAPY, BY APPLICATION TYPE, 2025-2033 ($MILLION)
  • TABLE 64. SOUTH KOREA REPERFUSION THERAPY, BY DRUG, 2025-2033 ($MILLION)
  • TABLE 65. SOUTH KOREA REPERFUSION THERAPY, BY END USER, 2025-2033 ($MILLION)
  • TABLE 66. AUSTRALIA REPERFUSION THERAPY, BY APPLICATION TYPE, 2025-2033 ($MILLION)
  • TABLE 67. AUSTRALIA REPERFUSION THERAPY, BY DRUG, 2025-2033 ($MILLION)
  • TABLE 68. AUSTRALIA REPERFUSION THERAPY, BY END USER, 2025-2033 ($MILLION)
  • TABLE 69. THAILAND REPERFUSION THERAPY, BY APPLICATION TYPE, 2025-2033 ($MILLION)
  • TABLE 70. THAILAND REPERFUSION THERAPY, BY DRUG, 2025-2033 ($MILLION)
  • TABLE 71. THAILAND REPERFUSION THERAPY, BY END USER, 2025-2033 ($MILLION)
  • TABLE 72. MALAYSIA REPERFUSION THERAPY, BY APPLICATION TYPE, 2025-2033 ($MILLION)
  • TABLE 73. MALAYSIA REPERFUSION THERAPY, BY DRUG, 2025-2033 ($MILLION)
  • TABLE 74. MALAYSIA REPERFUSION THERAPY, BY END USER, 2025-2033 ($MILLION)
  • TABLE 75. INDONESIA REPERFUSION THERAPY, BY APPLICATION TYPE, 2025-2033 ($MILLION)
  • TABLE 76. INDONESIA REPERFUSION THERAPY, BY DRUG, 2025-2033 ($MILLION)
  • TABLE 77. INDONESIA REPERFUSION THERAPY, BY END USER, 2025-2033 ($MILLION)
  • TABLE 78. REST OF ASIA PACIFIC REPERFUSION THERAPY, BY APPLICATION TYPE, 2025-2033 ($MILLION)
  • TABLE 79. REST OF ASIA PACIFIC REPERFUSION THERAPY, BY DRUG, 2025-2033 ($MILLION)
  • TABLE 80. REST OF ASIA PACIFIC REPERFUSION THERAPY, BY END USER, 2025-2033 ($MILLION)
  • TABLE 81. LAMEA REPERFUSION THERAPY, BY REGION, 2025-2033 ($MILLION)
  • TABLE 82. LAMEA REPERFUSION THERAPY, BY APPLICATION TYPE, 2025-2033 ($MILLION)
  • TABLE 83. LAMEA REPERFUSION THERAPY, BY DRUG, 2025-2033 ($MILLION)
  • TABLE 84. LAMEA REPERFUSION THERAPY, BY END USER, 2025-2033 ($MILLION)
  • TABLE 85. BRAZIL REPERFUSION THERAPY, BY APPLICATION TYPE, 2025-2033 ($MILLION)
  • TABLE 86. BRAZIL REPERFUSION THERAPY, BY DRUG, 2025-2033 ($MILLION)
  • TABLE 87. BRAZIL REPERFUSION THERAPY, BY END USER, 2025-2033 ($MILLION)
  • TABLE 88. SOUTH AFRICA REPERFUSION THERAPY, BY APPLICATION TYPE, 2025-2033 ($MILLION)
  • TABLE 89. SOUTH AFRICA REPERFUSION THERAPY, BY DRUG, 2025-2033 ($MILLION)
  • TABLE 90. SOUTH AFRICA REPERFUSION THERAPY, BY END USER, 2025-2033 ($MILLION)
  • TABLE 91. SAUDI ARABIA REPERFUSION THERAPY, BY APPLICATION TYPE, 2025-2033 ($MILLION)
  • TABLE 92. SAUDI ARABIA REPERFUSION THERAPY, BY DRUG, 2025-2033 ($MILLION)
  • TABLE 93. SAUDI ARABIA REPERFUSION THERAPY, BY END USER, 2025-2033 ($MILLION)
  • TABLE 94. UAE REPERFUSION THERAPY, BY APPLICATION TYPE, 2025-2033 ($MILLION)
  • TABLE 95. UAE REPERFUSION THERAPY, BY DRUG, 2025-2033 ($MILLION)
  • TABLE 96. UAE REPERFUSION THERAPY, BY END USER, 2025-2033 ($MILLION)
  • TABLE 97. ARGENTINA REPERFUSION THERAPY, BY APPLICATION TYPE, 2025-2033 ($MILLION)
  • TABLE 98. ARGENTINA REPERFUSION THERAPY, BY DRUG, 2025-2033 ($MILLION)
  • TABLE 99. ARGENTINA REPERFUSION THERAPY, BY END USER, 2025-2033 ($MILLION)
  • TABLE 100. REST OF LAMEA REPERFUSION THERAPY, BY APPLICATION TYPE, 2025-2033 ($MILLION)
  • TABLE 101. REST OF LAMEA REPERFUSION THERAPY, BY DRUG, 2025-2033 ($MILLION)
  • TABLE 102. REST OF LAMEA REPERFUSION THERAPY, BY END USER, 2025-2033 ($MILLION)
  • TABLE 103. CORLINE BIOMEDICAL AB: KEY EXECUTIVES
  • TABLE 104. CORLINE BIOMEDICAL AB: COMPANY SNAPSHOT
  • TABLE 105. CORLINE BIOMEDICAL AB: OPERATING SEGMENTS
  • TABLE 106. CORLINE BIOMEDICAL AB: PRODUCT PORTFOLIO
  • TABLE 107. CORLINE BIOMEDICAL AB: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 108. SBI HOLDINGS INC.: KEY EXECUTIVES
  • TABLE 109. SBI HOLDINGS INC.: COMPANY SNAPSHOT
  • TABLE 110. SBI HOLDINGS INC.: OPERATING SEGMENTS
  • TABLE 111. SBI HOLDINGS INC.: PRODUCT PORTFOLIO
  • TABLE 112. SBI HOLDINGS INC.: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 113. PHARMING GROUP NV: KEY EXECUTIVES
  • TABLE 114. PHARMING GROUP NV: COMPANY SNAPSHOT
  • TABLE 115. PHARMING GROUP NV: OPERATING SEGMENTS
  • TABLE 116. PHARMING GROUP NV: PRODUCT PORTFOLIO
  • TABLE 117. PHARMING GROUP NV: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 118. MALLINCKRODT PHARMACEUTICALS: KEY EXECUTIVES
  • TABLE 119. MALLINCKRODT PHARMACEUTICALS: COMPANY SNAPSHOT
  • TABLE 120. MALLINCKRODT PHARMACEUTICALS: OPERATING SEGMENTS
  • TABLE 121. MALLINCKRODT PHARMACEUTICALS: PRODUCT PORTFOLIO
  • TABLE 122. MALLINCKRODT PHARMACEUTICALS: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 123. MIFCOR, INC.: KEY EXECUTIVES
  • TABLE 124. MIFCOR, INC.: COMPANY SNAPSHOT
  • TABLE 125. MIFCOR, INC.: OPERATING SEGMENTS
  • TABLE 126. MIFCOR, INC.: PRODUCT PORTFOLIO
  • TABLE 127. MIFCOR, INC.: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 128. CFM PHARMA HOLDING B.V.: KEY EXECUTIVES
  • TABLE 129. CFM PHARMA HOLDING B.V.: COMPANY SNAPSHOT
  • TABLE 130. CFM PHARMA HOLDING B.V.: OPERATING SEGMENTS
  • TABLE 131. CFM PHARMA HOLDING B.V.: PRODUCT PORTFOLIO
  • TABLE 132. CFM PHARMA HOLDING B.V.: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 133. BALMES TRANSPLANTATION SAS: KEY EXECUTIVES
  • TABLE 134. BALMES TRANSPLANTATION SAS: COMPANY SNAPSHOT
  • TABLE 135. BALMES TRANSPLANTATION SAS: OPERATING SEGMENTS
  • TABLE 136. BALMES TRANSPLANTATION SAS: PRODUCT PORTFOLIO
  • TABLE 137. BALMES TRANSPLANTATION SAS: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 138. REVIVE THERAPEUTICS LTD.: KEY EXECUTIVES
  • TABLE 139. REVIVE THERAPEUTICS LTD.: COMPANY SNAPSHOT
  • TABLE 140. REVIVE THERAPEUTICS LTD.: OPERATING SEGMENTS
  • TABLE 141. REVIVE THERAPEUTICS LTD.: PRODUCT PORTFOLIO
  • TABLE 142. REVIVE THERAPEUTICS LTD.: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 143. FARADAY PHARMACEUTICALS: KEY EXECUTIVES
  • TABLE 144. FARADAY PHARMACEUTICALS: COMPANY SNAPSHOT
  • TABLE 145. FARADAY PHARMACEUTICALS: OPERATING SEGMENTS
  • TABLE 146. FARADAY PHARMACEUTICALS: PRODUCT PORTFOLIO
  • TABLE 147. FARADAY PHARMACEUTICALS: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 148. RADIKAL THERAPEUTICS INC.: KEY EXECUTIVES
  • TABLE 149. RADIKAL THERAPEUTICS INC.: COMPANY SNAPSHOT
  • TABLE 150. RADIKAL THERAPEUTICS INC.: OPERATING SEGMENTS
  • TABLE 151. RADIKAL THERAPEUTICS INC.: PRODUCT PORTFOLIO
  • TABLE 152. RADIKAL THERAPEUTICS INC.: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 153. AMYNDAS PHARMACEUTICALS: KEY EXECUTIVES
  • TABLE 154. AMYNDAS PHARMACEUTICALS: COMPANY SNAPSHOT
  • TABLE 155. AMYNDAS PHARMACEUTICALS: OPERATING SEGMENTS
  • TABLE 156. AMYNDAS PHARMACEUTICALS: PRODUCT PORTFOLIO
  • TABLE 157. AMYNDAS PHARMACEUTICALS: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 158. ANGION BIOMEDICA CORP.: KEY EXECUTIVES
  • TABLE 159. ANGION BIOMEDICA CORP.: COMPANY SNAPSHOT
  • TABLE 160. ANGION BIOMEDICA CORP.: OPERATING SEGMENTS
  • TABLE 161. ANGION BIOMEDICA CORP.: PRODUCT PORTFOLIO
  • TABLE 162. ANGION BIOMEDICA CORP.: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • LIST OF FIGURES

  • FIGURE 1. GLOBAL REPERFUSION THERAPY MARKET SEGMENTATION
  • FIGURE 2. GLOBAL REPERFUSION THERAPY MARKET
  • FIGURE 3. SEGMENTATION REPERFUSION THERAPY MARKET
  • FIGURE 4. TOP INVESTMENT POCKET IN REPERFUSION THERAPY MARKET
  • FIGURE 5. MODERATE BARGAINING POWER OF BUYERS
  • FIGURE 6. MODERATE BARGAINING POWER OF SUPPLIERS
  • FIGURE 7. MODERATE THREAT OF NEW ENTRANTS
  • FIGURE 8. LOW THREAT OF SUBSTITUTION
  • FIGURE 9. HIGH COMPETITIVE RIVALRY
  • FIGURE 10. OPPORTUNITIES, RESTRAINTS AND DRIVERS: GLOBALREPERFUSION THERAPY MARKET
  • FIGURE 11. REPERFUSION THERAPY MARKET SEGMENTATION, BY BY APPLICATION TYPE
  • FIGURE 12. REPERFUSION THERAPY MARKET FOR CORONARY ANGIOPLASTY, BY COUNTRY, 2025-2033 ($MILLION)
  • FIGURE 13. REPERFUSION THERAPY MARKET FOR CORONARY ARTERY PASS SURGERY, BY COUNTRY, 2025-2033 ($MILLION)
  • FIGURE 14. REPERFUSION THERAPY MARKET SEGMENTATION, BY BY DRUG
  • FIGURE 15. REPERFUSION THERAPY MARKET FOR FIBRINOLYTICS, BY COUNTRY, 2025-2033 ($MILLION)
  • FIGURE 16. REPERFUSION THERAPY MARKET FOR THROMBOLYTICS, BY COUNTRY, 2025-2033 ($MILLION)
  • FIGURE 17. REPERFUSION THERAPY MARKET SEGMENTATION, BY BY END USER
  • FIGURE 18. REPERFUSION THERAPY MARKET FOR HOSPITALS, BY COUNTRY, 2025-2033 ($MILLION)
  • FIGURE 19. REPERFUSION THERAPY MARKET FOR AMBULATORY SURGERY CENTERS, BY COUNTRY, 2025-2033 ($MILLION)
  • FIGURE 20. REPERFUSION THERAPY MARKET FOR OTHERS, BY COUNTRY, 2025-2033 ($MILLION)
  • FIGURE 21. TOP WINNING STRATEGIES, BY YEAR, 2022-2024*
  • FIGURE 22. TOP WINNING STRATEGIES, BY DEVELOPMENT, 2022-2024*
  • FIGURE 23. TOP WINNING STRATEGIES, BY COMPANY, 2022-2024*
  • FIGURE 24. PRODUCT MAPPING OF TOP 10 PLAYERS
  • FIGURE 25. COMPETITIVE DASHBOARD
  • FIGURE 26. COMPETITIVE HEATMAP: REPERFUSION THERAPY MARKET
  • FIGURE 27. TOP PLAYER POSITIONING, 2024
  • FIGURE 28. CORLINE BIOMEDICAL AB: NET SALES, 2022-2024 ($MILLION)
  • FIGURE 29. CORLINE BIOMEDICAL AB: REVENUE SHARE, BY SEGMENT, 2024 (%)
  • FIGURE 30. CORLINE BIOMEDICAL AB: REVENUE SHARE, BY REGION, 2024 (%)
  • FIGURE 31. SBI HOLDINGS INC.: NET SALES, 2022-2024 ($MILLION)
  • FIGURE 32. SBI HOLDINGS INC.: REVENUE SHARE, BY SEGMENT, 2024 (%)
  • FIGURE 33. SBI HOLDINGS INC.: REVENUE SHARE, BY REGION, 2024 (%)
  • FIGURE 34. PHARMING GROUP NV: NET SALES, 2022-2024 ($MILLION)
  • FIGURE 35. PHARMING GROUP NV: REVENUE SHARE, BY SEGMENT, 2024 (%)
  • FIGURE 36. PHARMING GROUP NV: REVENUE SHARE, BY REGION, 2024 (%)
  • FIGURE 37. MALLINCKRODT PHARMACEUTICALS: NET SALES, 2022-2024 ($MILLION)
  • FIGURE 38. MALLINCKRODT PHARMACEUTICALS: REVENUE SHARE, BY SEGMENT, 2024 (%)
  • FIGURE 39. MALLINCKRODT PHARMACEUTICALS: REVENUE SHARE, BY REGION, 2024 (%)
  • FIGURE 40. MIFCOR, INC.: NET SALES, 2022-2024 ($MILLION)
  • FIGURE 41. MIFCOR, INC.: REVENUE SHARE, BY SEGMENT, 2024 (%)
  • FIGURE 42. MIFCOR, INC.: REVENUE SHARE, BY REGION, 2024 (%)
  • FIGURE 43. CFM PHARMA HOLDING B.V.: NET SALES, 2022-2024 ($MILLION)
  • FIGURE 44. CFM PHARMA HOLDING B.V.: REVENUE SHARE, BY SEGMENT, 2024 (%)
  • FIGURE 45. CFM PHARMA HOLDING B.V.: REVENUE SHARE, BY REGION, 2024 (%)
  • FIGURE 46. BALMES TRANSPLANTATION SAS: NET SALES, 2022-2024 ($MILLION)
  • FIGURE 47. BALMES TRANSPLANTATION SAS: REVENUE SHARE, BY SEGMENT, 2024 (%)
  • FIGURE 48. BALMES TRANSPLANTATION SAS: REVENUE SHARE, BY REGION, 2024 (%)
  • FIGURE 49. REVIVE THERAPEUTICS LTD.: NET SALES, 2022-2024 ($MILLION)
  • FIGURE 50. REVIVE THERAPEUTICS LTD.: REVENUE SHARE, BY SEGMENT, 2024 (%)
  • FIGURE 51. REVIVE THERAPEUTICS LTD.: REVENUE SHARE, BY REGION, 2024 (%)
  • FIGURE 52. FARADAY PHARMACEUTICALS: NET SALES, 2022-2024 ($MILLION)
  • FIGURE 53. FARADAY PHARMACEUTICALS: REVENUE SHARE, BY SEGMENT, 2024 (%)
  • FIGURE 54. FARADAY PHARMACEUTICALS: REVENUE SHARE, BY REGION, 2024 (%)
  • FIGURE 55. RADIKAL THERAPEUTICS INC.: NET SALES, 2022-2024 ($MILLION)
  • FIGURE 56. RADIKAL THERAPEUTICS INC.: REVENUE SHARE, BY SEGMENT, 2024 (%)
  • FIGURE 57. RADIKAL THERAPEUTICS INC.: REVENUE SHARE, BY REGION, 2024 (%)
  • FIGURE 58. AMYNDAS PHARMACEUTICALS: NET SALES, 2022-2024 ($MILLION)
  • FIGURE 59. AMYNDAS PHARMACEUTICALS: REVENUE SHARE, BY SEGMENT, 2024 (%)
  • FIGURE 60. AMYNDAS PHARMACEUTICALS: REVENUE SHARE, BY REGION, 2024 (%)
  • FIGURE 61. ANGION BIOMEDICA CORP.: NET SALES, 2022-2024 ($MILLION)
  • FIGURE 62. ANGION BIOMEDICA CORP.: REVENUE SHARE, BY SEGMENT, 2024 (%)
  • FIGURE 63. ANGION BIOMEDICA CORP.: REVENUE SHARE, BY REGION, 2024 (%)

Purchase Full Report of
Reperfusion Therapy Market

PURCHASE OPTIONS



* Taxes/Fees, If applicable will be added during checkout. All prices in USD.

Have a question ?

Need to add more ?

Avail up to 30% discount on subscription plans on


Avenue